EUCTR2013-001154-98-GB进行中（未招募）1 期
Interventional, randomized, double-blind, cross-over, placebo-controlled study to investigate the effects of nalmefene after single dose on the blood oxygen level dependent (BOLD) fMRI signal in the ventral striatum to reward responding in the monetary incentive delay task (MIDT), in non-treatment seeking subjects with alcohol dependence following alcohol challenge (13-506) - fMRI scan study to find out how nalmefene works (ver 1)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •Men aged 20-65 years; drink, on average, at least 7½ units of alcohol daily; have drunk more than 7½ units of alcohol on at least 6 days in the last 4 weeks; willing and able to go without alcohol for one 3-night stay and one 2-night stay on the ward (but participants will have a slow injection of alcohol on each of the 3 full days they spend on the ward); in general good health, as judged by medical history, medical examination, vital signs, ECG and clinical laboratory tests (people who are alcohol-dependent are likely to have increased blood levels of substances linked to liver damage, so people with levels above the upper limit of the normal range for healthy men can be included at the discretion of the investigator); breath alcohol less than 0.02% at screening (when consent is given); able to communicate with study personnel; reliable, willing, and likely to comply with the protocol; willing to comply with the contraception and sperm donation requirements of the protocol; and consent to our informing their GP of their participation in the study, and to our entering their details into the over-volunteering database (TOPS).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 22
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •We exclude participants who meet the following criteria:
- •* have had more than 5 alcohol-free days in a row in the last 4 weeks; seeking or receiving treatment for alcohol dependence; have taken part in a support program (such as Alcoholics Anonymous) for alcohol dependence in the last 4 weeks; have taken medicines to treat alcohol dependence in the last 3 months— because participants must be able to tolerate injections of alcohol, and it would be unethical to ask participants seeking treatment for a drinking problem to expose themselves to alcohol;
- •* at risk of, or has experienced, alcohol withdrawal; poor general health; abuse of drugs; breath alcohol greater than 0.02% at the screening visit; have ever taken medicines to treat ‘fits’ (seizures), type I diabetes, or cancer; have taken certain medicines in the 2 months before the study; have had a serious reaction to any medicine; unable to process certain sugars; have had any condition or operation that might affect the way the body absorbs medicines; have had any clinically significant disease or condition; at risk of suicide; had a major operation within the last 6 months; have taken part in a clinical trial of nalmefene; objection by GP on medical grounds — because they might increase the risk, or confound the assessment of nalmefene; mental illness or intoxication might compromise consent;
- •* unwilling to comply with the contraception requirements of the protocol — because of the potential risk to babies conceived during the study;
- •* claustrophobia; any condition which would make it difficult to lie still for very long; metal in the body (eg pacemaker, mechanical heart valve, artificial limb, replacement hip joint, shrapnel); have worked as a metal worker, machinist or welder; have a lot of tattoos — because participants must have 2 fMRI scans during the study;
- •* employees of HMR, Imanova or the Faculty of Medicine at Imperial College; or close relatives of employees of HMR, Imanova or the Faculty of Medicine at Imperial College — because that is the policy of the sponsor, and to protect the confidentiality of employees; or
- •* have donated blood, or taken part in another study, within the past 1 month; or don't agree not to donate blood, or take part in another study, during the 1 month after this study — because participants shouldn't expose themselves to unnecessary medicines more often than a few times a year, nor should they donate too much blood;
- •We’ll study alcohol-dependent participants in good general health who are not seeking or receiving treatment for their drinking because:
- •* the study medicine is used to treat alcohol dependence
- •* the study requires participants to tolerate a slow injection of alcohol while lying in a scanner for up to 2 h, and remain alert so that they can complete our tests
- •* it would be unethical to ask people undergoing or seeking treatment for a drinking problem to expose themselves to alcohol.
研究者
相似试验
已完成
不适用
Interventional, randomised, partial double-blind, placebo- and positive controlled, multiple-dose, 4-way-cross-over trial Investigating the effect of arimoclomol on cardiac repolarization in healthy men.protein aggregation and protein misfolding diseases (lysosomal storage diseases and neuromuscular disorders such as ALSNL-OMON49378Orphazyme A/S32
已完成
不适用
Interventional, randomised, double-blind, sequential-group, placebo-controlled single ascending dose study investigating the safety, tolerability, and pharmacokinetic properties of Lu AF34134 in healthy young men and healthy elderly men and women, and open-label, three-period crossover, food interaction study of Lu AF34134 in healthy elderly men and women.10028037Parkinson's diseaseNL-OMON37707undbeck102
已完成
不适用
Interventional, randomized, double-blind, sequential-group, placebo-controlled, single-ascending-oral-dose study investigating the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of Lu AF88434 and open-label crossover study to investigate the intra-individual variability, metabolic profile, and effect of food on Lu AF88434 in healthy young mepsychiatric and neurologicalneurological diseasespsychiatric diseasesNL-OMON48259H. Lundbeck A/S84
进行中（未招募）
不适用
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentMedDRA version: 16.1Level: LLTClassification code 10025461Term: Major depressive disorder, recurrent episode, severe degree, without mention of psychotic behaviorSystem Organ Class: 100000004873MedDRA version: 16.1Level: LLTClassification code 10025462Term: Major depressive disorder, recurrent episode, unspecified degreeSystem Organ Class: 100000004873MedDRA version: 16.1Level: LLTClassification code 10025457Term: Major depressive disorder, recurrent episode, mild degreeSystem Organ Class: 100000004873MedDRA version: 16.1Level: LLTClassification code 10025458Term: Major depressive disorder, recurrent episode, moderate degreeSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2012-001361-32-FIH. Lundbeck A/S1,922
进行中（未招募）
不适用
Brexpiprazole as an additional treatment to paroxetine or sertraline in adult patients suffering from post-traumatic stress disorder (PTSD)EUCTR2012-004982-41-PLH. Lundbeck A/S790